210 related articles for article (PubMed ID: 32461361)
1. USP37 promotes deubiquitination of HIF2α in kidney cancer.
Hong K; Hu L; Liu X; Simon JM; Ptacek TS; Zheng X; Liao C; Baldwin AS; Zhang Q
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):13023-13032. PubMed ID: 32461361
[TBL] [Abstract][Full Text] [Related]
2. USP13 promotes deubiquitination of ZHX2 and tumorigenesis in kidney cancer.
Xie H; Zhou J; Liu X; Xu Y; Hepperla AJ; Simon JM; Wang T; Yao H; Liao C; Baldwin AS; Gong K; Zhang Q
Proc Natl Acad Sci U S A; 2022 Sep; 119(36):e2119854119. PubMed ID: 36037364
[TBL] [Abstract][Full Text] [Related]
3. Junction plakoglobin regulates and destabilizes HIF2α to inhibit tumorigenesis of renal cell carcinoma.
Chen K; Zeng J; Sun Y; Ouyang W; Yu G; Zhou H; Zhang Y; Yao W; Xiao W; Hu J; Xing J; Xiao K; Wu L; Chen Z; Ye Z; Xu H
Cancer Commun (Lond); 2021 Apr; 41(4):316-332. PubMed ID: 33591636
[TBL] [Abstract][Full Text] [Related]
4. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
5. CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells.
Trac N; Oh HS; Jones LI; Caliliw R; Ohtake S; Shuch B; Chung EJ
Molecules; 2022 Dec; 27(23):. PubMed ID: 36500549
[TBL] [Abstract][Full Text] [Related]
6. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis.
Liu XD; Yao J; Tripathi DN; Ding Z; Xu Y; Sun M; Zhang J; Bai S; German P; Hoang A; Zhou L; Jonasch D; Zhang X; Conti CJ; Efstathiou E; Tannir NM; Eissa NT; Mills GB; Walker CL; Jonasch E
Oncogene; 2015 May; 34(19):2450-60. PubMed ID: 24998849
[TBL] [Abstract][Full Text] [Related]
7. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
[TBL] [Abstract][Full Text] [Related]
8. HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma.
Qiu B; Ackerman D; Sanchez DJ; Li B; Ochocki JD; Grazioli A; Bobrovnikova-Marjon E; Diehl JA; Keith B; Simon MC
Cancer Discov; 2015 Jun; 5(6):652-67. PubMed ID: 25829424
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss.
Liu X; Simon JM; Xie H; Hu L; Wang J; Zurlo G; Fan C; Ptacek TS; Herring L; Tan X; Li M; Baldwin AS; Kim WY; Wu T; Kirschner MW; Gong K; Zhang Q
Mol Cell; 2020 Mar; 77(6):1294-1306.e5. PubMed ID: 32023483
[TBL] [Abstract][Full Text] [Related]
10. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
[TBL] [Abstract][Full Text] [Related]
11. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.
Mathew LK; Lee SS; Skuli N; Rao S; Keith B; Nathanson KL; Lal P; Simon MC
Cancer Discov; 2014 Jan; 4(1):53-60. PubMed ID: 24189146
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor modulates metastatic routes of VHL wild-type clear cell renal cell carcinoma in an oxygen-dependent manner.
Huang Q; Sun Y; Zhai W; Ma X; Shen D; Du S; You B; Niu Y; Huang CP; Zhang X; Chang C
Oncogene; 2020 Oct; 39(43):6677-6691. PubMed ID: 32943729
[TBL] [Abstract][Full Text] [Related]
13. A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma.
Wallace EM; Rizzi JP; Han G; Wehn PM; Cao Z; Du X; Cheng T; Czerwinski RM; Dixon DD; Goggin BS; Grina JA; Halfmann MM; Maddie MA; Olive SR; Schlachter ST; Tan H; Wang B; Wang K; Xie S; Xu R; Yang H; Josey JA
Cancer Res; 2016 Sep; 76(18):5491-500. PubMed ID: 27635045
[TBL] [Abstract][Full Text] [Related]
14. NADPH oxidase NOX4 supports renal tumorigenesis by promoting the expression and nuclear accumulation of HIF2α.
Gregg JL; Turner RM; Chang G; Joshi D; Zhan Y; Chen L; Maranchie JK
Cancer Res; 2014 Jul; 74(13):3501-3511. PubMed ID: 24755467
[TBL] [Abstract][Full Text] [Related]
15.
Yao X; Tan J; Lim KJ; Koh J; Ooi WF; Li Z; Huang D; Xing M; Chan YS; Qu JZ; Tay ST; Wijaya G; Lam YN; Hong JH; Lee-Lim AP; Guan P; Ng MSW; He CZ; Lin JS; Nandi T; Qamra A; Xu C; Myint SS; Davies JOJ; Goh JY; Loh G; Tan BC; Rozen SG; Yu Q; Tan IBH; Cheng CWS; Li S; Chang KTE; Tan PH; Silver DL; Lezhava A; Steger G; Hughes JR; Teh BT; Tan P
Cancer Discov; 2017 Nov; 7(11):1284-1305. PubMed ID: 28893800
[TBL] [Abstract][Full Text] [Related]
16. The role of HIF1α in renal cell carcinoma tumorigenesis.
Gudas LJ; Fu L; Minton DR; Mongan NP; Nanus DM
J Mol Med (Berl); 2014 Aug; 92(8):825-36. PubMed ID: 24916472
[TBL] [Abstract][Full Text] [Related]
17. HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.
Elorza A; Soro-Arnáiz I; Meléndez-Rodríguez F; Rodríguez-Vaello V; Marsboom G; de Cárcer G; Acosta-Iborra B; Albacete-Albacete L; Ordóñez A; Serrano-Oviedo L; Giménez-Bachs JM; Vara-Vega A; Salinas A; Sánchez-Prieto R; Martín del Río R; Sánchez-Madrid F; Malumbres M; Landázuri MO; Aragonés J
Mol Cell; 2012 Dec; 48(5):681-91. PubMed ID: 23103253
[TBL] [Abstract][Full Text] [Related]
18. HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma.
Wong SC; Cheng W; Hamilton H; Nicholas AL; Wakefield DH; Almeida A; Blokhin AV; Carlson J; Neal ZC; Subbotin V; Zhang G; Hegge J; Bertin S; Trubetskoy VS; Rozema DB; Lewis DL; Kanner SB
Mol Cancer Ther; 2018 Jan; 17(1):140-149. PubMed ID: 29079709
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma.
Ma X; Shen D; Li H; Zhang Y; Lv X; Huang Q; Gao Y; Li X; Gu L; Xiu S; Bao X; Duan J; Zhang X
Urol Oncol; 2015 Apr; 33(4):169.e1-11. PubMed ID: 25700976
[TBL] [Abstract][Full Text] [Related]
20. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
